Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Global Blood Therapeutic sees its Relative Strength Rating move into the 80-plus level.

Stocks With Rising Relative Price Strength: Global Blood Therapeutic

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD

New Drug Application submission, including new age-appropriate formulation, planned by mid-2021

GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Global Blood (GBT) Down 16.3% Since Last Earnings Report: Can It Rebound?

Here's why it is now a great opportunity to buy a company making an innovative therapy for patients with sickle cell disease.

Is Global Blood Therapeutics a Buy?

Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry

SOUTH SAN FRANCISCO, Calif., May  07, 2020  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees restricted stock units for an aggregate of 36,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

GBT Announces  New Employment Inducement Grants

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call Transcript

Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates

Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Global Blood (GBT) Ahead of Earnings?

On Wednesday, investors will learn the progress of its sickle cell disease drug launch.

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

CRISPR Therapeutics

Novartis

Vertex Pharmaceuticals

Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.

What's The Best Biotech Stock to Buy for Treating Sickle Cell Disease?

Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit Continues

Newly created GBT Community Fund to provide $150,000 in grants to U.S. non-profits addressing the needs of the sickle cell disease community

GBT Commits $250,000 to Support the Sickle Cell Disease Community During COVID-19 Pandemic

Why Is Global Blood (GBT) Down 15% Since Last Earnings Report?

Despite fears of a COVID-19 pandemic, these two stocks are worth considering.

2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market

SOUTH SAN FRANCISCO, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2020, the compensation committee of GBT’s board of directors granted four new employees restricted stock units for an aggregate of 15,550 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

GBT Announces New Employment Inducement Grants (GBT)

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.

Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2019 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Feb.  20, 2020  (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for its Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which provides grant funding to expand novel access-to-care programs for people living with sickle cell disease (SCD). In 2020, the ACCEL program will fund up to five proposals, providing a grant of up to $50,000 each. GBT created the program in 2019 to accelerate the development of innovative and sustainable programs that have the potential over time to improve access to quality healthcare for people living with this lifelong inherited blood disorder.

GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Disease

Exact Sciences

CarMax

Lennar

L3Harris

Noble Energy

Cloudflare

Despite the level of uncertainty as we enter 2020, we've found seven stocks that look like the new decade’s showstoppers.

7 Stocks That Are Screaming Buys Right Now

Amarin Corporation Plc

Clovis Oncology

These companies could kick off the year with big announcements and deliver gains to savvy investors.

3 Top Biotech Stocks to Buy in January

Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.

Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta

bluebird bio

Amicus Therapeutics

Intercept Pharma

uniQure

5 Best Mid-Cap Biotech Acquisition Targets

Alnylam Pharmaceuticals

Patients who inherit life-threatening blood disorders have some important new treatment options.

News for Global Blood Therapeutics Stock (GBT)